PTGS2 and non-small cell lung carcinoma: This phase 2 randomized clinical trial evaluates the effect of combined selective cyclooxygenase 2 (COX-2) inhibition with standard concurrent chemoradiation therapy vs concurrent chemoradiation alone on survival among patients with unresectable stage III non–small cell lung cancer (NSCLC).